ArticleCirculation. Population health and outcomes2026
Metabolic Vulnerability Index and Risk of Total Mortality: Findings From the Multi-Ethnic Study of Atherosclerosis.
Article in Circulation. Population health and outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundThe metabolic vulnerability index (MVX) is a composite score reflecting inflammatory, metabolic, and nutritional status. The objective of this study is to evaluate the association between MVX and mortality among adults without prevalent cardiovascular disease (CVD).
methodsUsing the MESA (Multi-Ethnic Study of Atherosclerosis), we examined 5887 adults from all participating MESA sites free of clinical CVD at baseline (2000-2002). MVX was measured using nuclear magnetic resonance metabolomics and included GlycA, small high-density lipoprotein particles, valine, leucine, isoleucine, and citrate. We assessed the association between MVX (categorized as quartiles; quartile 1 as referent) and total mortality (median follow-up, 17.9 years). Cox regression models adjusted for sociodemographic measures, behaviors, cardiometabolic factors, and incident disease were used to estimate hazard ratios. Analyses were repeated, stratified by incident CVD.
resultsAmong 5887 participants (mean age 61.6, 53% self-identified female), MVX scores ranged from 7.8 to 79.3, and mortality increased from 19.5% to 37.4% across quartiles during 94 351 person-years of follow-up. CVD- and non-CVD-related deaths separately demonstrated similarly higher rates in higher quartiles of MVX. Participants in the fourth quartile of MVX had a significantly higher risk for total mortality (hazard ratio, 1.73 [95% CI, 1.49-2.01]) during follow-up with minimal attenuation after adjustment for incident disease. In those with and without incident CVD during follow-up, the hazard ratio for mortality in the fourth quartile was 1.74 (95% CI, 1.38-2.20) and 1.68 (95% CI, 1.38-2.05), indicating a strong association with increased risk of death irrespective of CVD events.
conclusionsAmong mid-life adults free of clinical CVD at baseline, higher MVX scores were strongly and independently associated with future mortality, irrespective of incident morbidity-including CVD. These findings suggest that the MVX score offers unique insight into an individual's vulnerability to mortality beyond traditional risk factors and disease status.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.